Dr. Waqqas Afif
If you are interested in learning more about any of the clinical and research studies below or would like to volunteer as a research subject, please email: miirecherche.ibdresearch@muhc.mcgill.ca.
Collaboration with Dr. Greg Rosenfeld, University of British Columbia
Study Title: Pro-Active Fecal Calprotectin Monitoring to Improve Patient Outcomes in Ulcerative Colitis: A Prospective Randomized Control Trial (PROMOTE-UC)
Study Title: Pilot study to assess de-escalation of ustekinumab therapy in patients with Crohn’s disease
Study Title: Therapeutic drug monitoring guided early optimization of Adalimumab in Crohn’s disease. A randomized open-label study
Collaboration with Dr. Sasha Bernatsky, Research Institute of the McGill University Health Centre
Sponsor: Canadian Institutes of Health Research (CIHR)
Study Title: Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs
Study Title: A pilot study assessing performance of point-of-care testing for infliximab, adalimumab, C-reactive protein, and fecal calprotectin in inflammatory bowel disease patients with a secondary loss of response
Dr. Talat Bessisow
If you are interested in learning more about any of the clinical and research studies below or would like to volunteer as a research subject, please email: miirecherche.ibdresearch@muhc.mcgill.ca.
In collaboration with Dr. Sanjay Murthy, MD, MSc, FRCPC, University of Ottawa, The Ottawa Hospital – General Campus
Study Title: A Randomized Controlled Non-Inferiority Trial Comparing Neoplasia Detection During Colonoscopy Screening With and Without Non-Targeted Biopsies in Adult Colonic Inflammatory Bowel Disease
Sponsor : University Hospital Leuven, Herestraat 49, 3000 Leuven
Study Title: PRognOstiC valuE of rEd Density in Ulcerative Colitis: PROCEED-UC STUDY Predictive value of new endoscopic technique in ulcerative colitis
Collaboration with Dr. Saji George, Ph.D., Associate Professor, Canada Research Chair in Sustainable Nanotechnology for Food and Agriculture
Study Title: Effect of dietary nanomaterials on the development and disease progression of inflammatory bowel disease
Collaboration with Dr. Bruce Mazer
Study Title: Transdisciplinary Centre for Biological Therapies Biobank and Registry
Dr. Alain Bitton
If you are interested in learning more about any of the clinical and research studies below or would like to volunteer as a research subject, please email: miirecherche.ibdresearch@muhc.mcgill.ca.
The following 4 studies are part of NIH-NIDDK IBD Genetics Consortium (IBDGC)
- Identifying genes responsible for inflammatory bowel disease
- Mechanisms of microbiota in mucosal inflammation across the biologic demarcation of Ulcerative Colitis
- Mechanisms of intestinal inflammation following ileal resection for Crohn’s Disease
- Understanding the Genetics of Inflammatory Bowel Disease: The Diversity Study
Sponsor: Dr. John D. Rioux, Montreal Heart Institute
Funding: Génome Canada (Rioux), National Institutes of Health (Rioux) and Pfizer Canada Inc. (Rioux)
Study Title: iGenoMed – CHUM: Identification of biomarkers of response to molecularly-targeted therapies in inflammatory bowel diseases
Study Title: Inflammatory Bowel Disease Epidemiology, Future Burden and Cancer Risk in Québec and Canada (as part of an initiative by the Canadian Gastro-Intestinal Epidemiology Consortium) – pending approval
Dr. Alain Bitton & Dr. Terry Sigman
If you are interested in learning more about any of the clinical and research studies below or would like to volunteer as a research subject, please email: miirecherche.ibdresearch@muhc.mcgill.ca.
Sponsor: Dr. Kenneth Croitoru, Mount Sinai Hospital, Toronto ON with funding from Crohn’s and Colitis Canada
Study Title: A Multidisciplinary Human Study on the Genetic, Environmental and Microbial Interactions that Cause IBD (GEM Project)
Dr. Peter Lakatos
If you are interested in learning more about any of the clinical and research studies below or would like to volunteer as a research subject, please email Rita Kohen: rita.kohen@muhc.mcgill.ca
Study Title: Quality of Care Assessment of the MUHC IBD Center: Retrospective and Prospective Assessment of Quality or Care and Outcome Parameters before and after Installation of the IBD Center
Study Title: Clinical Outcomes and Therapeutic Drug Monitoring Following Switching from Intravenous Vedolizumab to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease; An Observational Study
Study Title: Clinical Efficacy and Safety Following Starting Risankizumab or Upadacitinib Treatment in Patients with Inflammatory Bowel Disease Who are Biological Naïve or with Prior Biological Therapy Failure: An Observational Study
Study Title: Biofabrication of a 3D gut-on-a-chip model of human inflammatory bowel disease